Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Mouse anti-Cytokeratin 17, Clone: KRT17/778, Novus Biologicals™

Mouse Monoclonal Antibody

Manufacturer:  Novus BiologicalsSupplier Diversity Partner NBP2444270.2MG

 View more versions of this product

Catalog No. NBP24442702

This item has been discontinued and is no longer available. Please call customer service for assistance: 1-800-766-7000.


Description

Description

Ensure accurate, reproducible results in Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Specifications

Specifications

Cytokeratin 17
KRT17/778
Unconjugated
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Purified
KRT17
Recombinant full-length human KRT17 protein
46 kDa
0.2 mg
Cancer
Primary
3872
Human, Rat, Porcine, Goat, Primate
Flow Cytometry, Immunohistochemistry (Paraffin), SDS-Page, Immunofluorescence
0.2mg/mL
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, SDS-Page, Immunofluorescence 1 - 2 ug/ml
Q04695
39.1, CK-17, cytokeratin-17, K17, keratin 17, keratin, type I cytoskeletal 17, keratin-17, PC, PC2, PCHC1
Mouse
IgG2b Kappa
Protein A or G purified
RUO
Store at 4C.
Monoclonal
Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.
Documents
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

For Research Use Only